| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Operating expenses: | | | | | | | | |
| Research and development | 3.7 | 4.3 | 1.4 | 0.6 | 10.5 | 8.8 | 9.1 | 7.4 |
| General and administrative | 5.5 | 5.0 | 2.9 | 0.1 | 3.4 | 5.0 | 4.6 | 5.2 |
| Total operating expenses | 9.1 | 9.3 | 4.3 | 0.7 | 13.8 | 13.8 | 13.7 | 12.7 |
| Loss from operations | -9.1 | -7.6 | -4.3 | -0.7 | -13.8 | -13.8 | -13.7 | -12.7 |
| |
| Other income (expense): | | | | | | | | |
| Interest expense, net | -2.0 | -2.0 | -0.7 | | | | | |
| Change in fair value of derivative on debt | 0.3 | 0.0 | 0.2 | | | | | |
| Loss on extinguishment / conversion of debt | 0.0 | -0.3 | | | | | | |
| Total other income (expense) | -1.4 | -2.4 | -2.3 | | | | | |
| Net income (loss) before non-controlling interests | -10.5 | -10.0 | -6.6 | | | | | |
| Net loss attributable to non-controlling interests | -1.1 | -0.5 | | | | | | |
| Net income (loss) attributable to Oncotelic Therapeutics, Inc. | -9.4 | -9.5 | -6.6 | -0.7 | -13.8 | -13.7 | -13.7 | -12.6 |
| |
| Basic net income (loss) per share attributable to common stock | ($0.03) | ($0.11) | ($0.11) | ($0.12) | ($0.52) | ($0.51) | ($0.54) | ($0.75) |
| |
| Basic weighted average common stock outstanding | 303.1 | 88.1 | 60.0 | 6.1 | 26.5 | 26.5 | 25.2 | 17.0 |